145 related articles for article (PubMed ID: 27416842)
1. Neutrophil-lymphocyte ratio as a prognostic marker for chemotherapy in advanced lung cancer.
Liu ZL; Zeng TT; Zhou XJ; Ren YN; Zhang L; Zhang XX; Ding ZY
Int J Biol Markers; 2016 Dec; 31(4):e395-e401. PubMed ID: 27416842
[TBL] [Abstract][Full Text] [Related]
2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
5. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Lee Y; Kim SH; Han JY; Kim HT; Yun T; Lee JS
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2009-16. PubMed ID: 22772951
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
7. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Xiong Y; Zhao N; Zheng Y; Wang J; Wei F; Ren X
Tumour Biol; 2017 Jun; 39(6):1010428317701639. PubMed ID: 28618954
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Yao Y; Yuan D; Liu H; Gu X; Song Y
Cancer Immunol Immunother; 2013 Mar; 62(3):471-9. PubMed ID: 22986452
[TBL] [Abstract][Full Text] [Related]
10. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Cancer Med; 2014 Apr; 3(2):406-15. PubMed ID: 24519894
[TBL] [Abstract][Full Text] [Related]
12. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.
Jin H; Zhang G; Liu X; Liu X; Chen C; Yu H; Huang X; Zhang Q; Yu J
World J Surg Oncol; 2013 May; 11():112. PubMed ID: 23705622
[TBL] [Abstract][Full Text] [Related]
13. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
14. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
[TBL] [Abstract][Full Text] [Related]
15. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ
Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
[TBL] [Abstract][Full Text] [Related]
19. Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
Xu H; Xu F; Zhu W; Ying J; Wang Y
Thorac Cancer; 2018 Aug; 9(8):1005-1011. PubMed ID: 29917332
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer.
Cedrés S; Torrejon D; Martínez A; Martinez P; Navarro A; Zamora E; Mulet-Margalef N; Felip E
Clin Transl Oncol; 2012 Nov; 14(11):864-9. PubMed ID: 22855161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
